Synopsis Multiple sclerosis (MS) is characterized as a disabling disease of the central nervous system. In MS, the myelin covering nerve fibers are targeted by the body’s immune system, causing communication problems between the brain and the rest of the body. Management focuses on speeding recovery, slowing disease progression, and symptomatic management. This Journal Watch summarizes the trial “ Safety and Efficacy of Rituximab in Multiple Sclerosis: A Retrospective Observational Study, ” published in the Hindawi Journal of Immunology, 2018 . Authors: B Yamout, N El-Ayoubi, J Nicolas, et al.
What was the need for this study? B-cells and humoral immunity play a key role in the pathogenesis of MS. Rituximab is an anti-CD 20 chimeric monoclonal antibody that depletes circulating B cells, altering B cell-mediated T cell activation, antibody production, and cytokine secretion. This study…
